Q-omics provides the consensus-scored C1orf131 profile across patient tissues and cancer cell-line models. C1orf131 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C1orf131 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, C1orf131 RNA expression shows 19,421 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where C1orf131 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf131 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf131 survival associations across molecular data types. C1orf131 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf131 RNA expression–survival associations across cancer types. High C1orf131 expression shows unfavorable associations in ACC, KIRP, LGG, UVM and KIRC, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C1orf131 RNA expression.
This table summarizes C1orf131 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C1orf131. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf131 shows higher tumor expression in HNSC, KIRC, STAD, BLCA, LIHC and LUAD. The HNSC box plot shows higher C1orf131 RNA expression in tumor versus normal tissue (log2 FC = +1.165, t-test p < 0.001).
This table shows molecular features associated with C1orf131 in patient tissues and cancer cell lines. In patient samples, C1orf131 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf131 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
